Biogen on Thursday shared news of the subpoena in its annual federal filing. The subpoena seeks information on federal price reporting, rebate payments and Biogen’s co-pay assistance programs for the treatments Tecfidera, Avonex, Tysabri and Plegridy,” according to the report.
The drugmaker increased the U.S. list prices of Tecfidera, Avonex and Plegridy by 8 percent and Tysabri by 3.5 percent. The price hikes went into effect Jan. 1.
The drugnaker said it was cooperating with the investigation, but offered no further details, reports Boston Business Journal.
In December, the company faced backlash after announcing a higher-than-expected price for its new spinal muscular atrophy treatment Spinraza, according to the report.
More articles on supply chain:
5 Trump quotes on drug prices explained
FDA OKs Opdivo for bladder cancer
7 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
